Shares of Ligand (NASDAQ: LGND) popped 13% today after its partner GlaxoSmithKline's (NYSE: GSK) drug Promacta received an additional indication (an FDA approval) to increase low blood platelet levels in cases of chronic hepatitis C. However, new advances in hepatitis C care are revolutionizing treatment ideas that may take the wind out of Ligand's sails.
Free Article
FDA Approval Victory a Yawner?
By Dave Williamson and Max Macaluso
–
Nov 19, 2012 at 4:07PM
NASDAQ: LGND
Ligand Pharmaceuticals
Market Cap
$1B
Today's Change
(-5.44%) -$3.94
Current Price
$68.53
Price as of April 22, 2024, 4:00 p.m. ET
Will Ligand's jump today be short lived?
David Williamson has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline and Vertex Pharmaceuticals. Motley Fool newsletter services recommend Gilead Sciences, GlaxoSmithKline, and Vertex Pharmaceuticals. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles
Ligand Pharmaceuticals Incorporated (LGND) Q3 2021 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) Q2 2021 Earnings Call Transcript
Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug
Ligand Pharmaceuticals Inc (LGND) Q1 2021 Earnings Call Transcript
3 Signs the Ligand Short Squeeze Is Over
606%
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.